December 3, 2018 Clinical Research/Diagn.

Bio-Rad Quality Controls Now Available for Multiple Abbott Clinical Diagnostics Platforms

Date: 12/03/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments. “We are pleased to fulfill this need and offer customers... Read more

November 30, 2018 Clinical Research/Diagn. Product Launch

QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs

Hilden, Germany, Germantown, Maryland, Fort Myers, Florida, November 30, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients. The partnership between QIAGEN and NeoGenomics, a leading provider of... Read more

November 29, 2018 Clinical Research/Diagn.

BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion

FRANKLIN LAKES, N.J., Nov. 29, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new software application designed to help hospitals and health systems identify drug diversion at the 2018 American Society of Health-System Pharmacists (ASHP) Midyear Meeting. Addiction to prescription narcotics in... Read more

November 27, 2018 Clinical Research/Diagn. Lab Top-10 Life Science Tools PR/Corporate

MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018

27 NOV 2018 | DARMSTADT, GERMANY MilliporeSigma’s proxy-CRISPR wins Special Recognition Market Disruptor — Products award Burlington, Massachusetts, November 27, 2018 – MilliporeSigma today announced that it has won two R&D 100 Awards. The 56th annual R&D 100 Awards program, honoring the 100 most innovative and significant technologies introduced in the past year, recognized MilliporeSigma for its BioReliance® Viral and Gene Therapy Assay... Read more

November 26, 2018 Clinical Research/Diagn. M&A, Partnerships

AddLife acquires Austrian Biomedica – international expansion on 13 new markets

26.11.2018 – 14:00 Life science group AddLife is continuing on its growth journey and is now taking an important step in its expansion and internationalisation strategy by acquiring Austrian Biomedica Medizinprodukte GmbH (“Biomedica”). Biomedica, which is the parent company of a group with sales of about EUR 65 million, engages in operations in 13 countries... Read more

November 26, 2018 Clinical Research/Diagn. M&A, Partnerships

Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies

KEELE, England, PORT WASHINGTON, N.Y. and LONDON, Nov. 26, 2018 /PRNewswire/ — Cobra Biologics, an international contract development and manufacturing organization (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5M shared grant from Innovate UK, the United Kingdom’s innovation agency. Co-winners, Pall Corporation, a global leader in filtration, separation and purification, and the Cell and Gene Therapy Catapult, an independent research and technology organization... Read more

November 19, 2018 Bio/Pharma/CRO Clinical Research/Diagn. Informatics & Software Product Launch

Lonza Opens Collaborative Innovation Center in Haifa, Israel

November 19,2018 Product News PDF New center will be a hub to identify and accelerate fresh solutions to rethink drug development and manufacturing Labs in the new facility, together with funding, will enable projects in collaboration with Israeli talent in academia, medical institutions and early-stage innovative companies Haifa (IL), 19 November 2018 – Lonza Pharma &... Read more

November 19, 2018 Clinical Research/Diagn. PR/Corporate

Two Pore Guys Receives $2.8M Grant to Develop Sensitive, Low-Cost Molecular Diagnostic Tests for Tuberculosis

Goal of Bill & Melinda Gates Foundation Grant Is to Improve TB Care in Resource-Poor Settings SANTA CRUZ, Calif.–(BUSINESS WIRE)–Two Pore Guys, Inc. (2PG) today announced that the company has received a $2.8 million grant from the Bill & Melinda Gates Foundation to develop sensitive, low-cost molecular diagnostic tests for tuberculosis (TB) using its solid-state nanopore technology.... Read more

November 19, 2018 Clinical Research/Diagn. M&A, Partnerships

Arrayit Corporation Announces Allergy Testing Agreement with Sutter Health

Sunnyvale, Nov. 05, 2018 (GLOBE NEWSWIRE) — Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces an allergy testing agreement with Northern California healthcare leader Sutter Health. The company is providing its proprietary microarray-based finger stick allergy testing services to Sutter Health via doctors in the Sutter Health-affiliated Palo Alto Medical Foundation. Sutter Health,... Read more